TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers found that older adults with faster cognitive decline had lower levels of the protective protein NRF2 in oligodendrocytes and abnormalities in myelin and nerve fibers. Mouse experiments support a possible causal role, but the findings do not show that NRF2-targeting drugs can prevent age-related decline in people.
Researchers led by the University of Edinburgh and the UK Dementia Research Institute report that dysfunction in oligodendrocytes—cells that maintain the brain’s myelin coating—may contribute to cognitive decline with age. The study, published in Nature Medicine, links lower levels of the protective protein NRF2 in these cells to abnormal myelin and damage to large nerve fibers in human brain tissue, while mouse experiments provide evidence that reducing NRF2 can cause similar changes.
The researchers studied members of the Lothian Birth Cohort 1936, whose cognitive abilities had been followed from childhood into old age. Of the 1,091 people enrolled, 866 completed additional assessments after age 70. Between ages 70 and 82, testing measured memory, information-processing speed and spatial reasoning. Participants experienced differing rates of decline, giving the team a way to compare brain tissue with changes in cognition over time.
After some participants died, researchers examined their brain tissue. Those who had declined more rapidly tended to have fewer large nerve fibers and abnormal accumulations of myelin, the insulating material that helps electrical signals travel along nerve fibers. The abnormalities were particularly apparent around the large fibers that remained. The researchers said these tissue findings were associated with the pace of cognitive decline, not simply with a person’s test performance at one particular age.
The team then focused on oligodendrocytes, which produce and maintain myelin. In people with greater decline, the researchers found lower levels of NRF2 in these cells. NRF2 regulates genes involved in cellular protection and normal function. In mice, selectively reducing NRF2 in oligodendrocytes led to excessive myelin, loss of large nerve fibers and less improvement in cognitive performance as the animals aged. The mouse results support a direct role for NRF2 loss in the observed changes, but they do not establish that the same chain of events explains cognitive decline in all older people.
A New Target in Brain Aging
The findings challenge the simple view that oligodendrocytes are always protective. These cells are necessary for healthy nerve signaling, but the study suggests that age-related dysfunction may make their effects harmful, including through abnormal myelin buildup and damage to nerve fibers. This offers researchers a possible way to investigate why cognitive abilities decline at different rates among people of similar ages.
The work also points to NRF2 activity as a potential research target. The pathway is already affected by drugs used for other neurological conditions, including multiple sclerosis. The researchers note that prior studies have found cognitive benefits from increasing NRF2 activity in people with MS. That history may help guide future investigation, but it is not evidence that these medicines prevent or treat age-related cognitive decline. Testing safety and benefit in older adults would require dedicated studies.
As an affiliate, we earn on qualifying purchases.
Decades of Cognitive Tracking
The cohort’s long-running records are a central part of the study: they allowed the researchers to relate later-life brain-tissue findings to measured changes in cognition across years, rather than relying only on a single test. The human analysis identified associations between greater decline, fewer large nerve fibers, abnormal myelin and lower oligodendrocyte NRF2. The experiments in mice added evidence that reducing NRF2 can produce similar biological changes.
Myelin normally insulates nerve fibers and supports efficient communication between brain cells. Oligodendrocytes maintain that coating, so changes in their function could affect both the insulation and the fibers themselves. The study’s findings suggest that the condition of this support system may matter to cognitive aging, alongside other biological processes. They do not establish that it is the sole or primary cause of decline.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
Human Treatment Evidence Is Missing
The human tissue findings are observational: they show that NRF2 levels and myelin and nerve-fiber abnormalities were associated with the pace of cognitive decline, but cannot by themselves prove that NRF2 loss caused that decline in participants. The mouse experiments strengthen the case for a biological mechanism, yet animal results do not establish that a drug will work in people.
The study does not show that existing NRF2-targeting medicines can slow age-related cognitive decline, which patients might benefit, or what dose or treatment period would be appropriate. The supplied study summary also does not give a specific clinical trial plan or timeline. Cognitive decline can have multiple causes, and the role of this pathway in different conditions and stages remains to be established.
Testing the NRF2 Pathway
The immediate next step is further research to determine how reduced NRF2 activity affects oligodendrocytes and whether the pathway can be safely adjusted in ways that protect nerve fibers in aging. Researchers would also need to establish whether the findings apply across broader groups of older adults and whether changes in this pathway track with meaningful differences in cognition.
Any use of existing medicines for age-related decline would require clinical studies designed for that purpose. Until such evidence is available, the research identifies a potential therapeutic target, not a treatment recommendation. No results from a trial of an NRF2-targeting drug for age-related cognitive decline were reported in the source material.
Key Questions
What brain cells did the study examine?
It focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers.
What is NRF2?
NRF2 is a protein that helps regulate genes involved in protecting cells and maintaining their normal function. The researchers found lower levels of it in oligodendrocytes in people with greater cognitive decline.
Does the study prove that NRF2 loss causes cognitive decline in people?
No. The human findings show an association. Experiments in mice provide evidence that reducing NRF2 can cause related brain changes in animals, but they do not prove the same mechanism causes decline in people.
The study raises that possibility because medicines for other conditions can affect the NRF2 pathway. It does not show that those drugs prevent or treat age-related decline; clinical trials would be needed to test that.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
